{
    "nctId": "NCT03083314",
    "briefTitle": "Selective Axillary Lymph Node Dissection Vs Complete Axillary Dissection: A Randomised Clinical Trial to Assess the Prevention of Lymphedema in Breast Cancer Treatment",
    "officialTitle": "SELECTIVE AXILLARY LYMPH NODE DISSECTION VS COMPLETE AXILLARY DISSECTION: A RANDOMISED CLINICAL TRIAL TO ASSESS THE PREVENTION OF LYMPHEDEMA IN BREAST CANCER TREATMENT",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "To compare the occurrence of breast-cancer-related lymphoedema (BCRL) after selective axillary dissection (SAD) and after axillary lymph node dissection (ALND)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients diagnosed with operable breast cancer who are candidates for ALND, irrespective of the type of breast surgery performed or adjuvant treatments administered.\n* Patients who sign the informed consent form after explanation of trial aims by a senologist involved in the study.\n* Patients able to attend INT for regular follow-up as required by study protocol.\n\nExclusion Criteria:\n\n* Massive axillary metastasis (N2 AJCC).\n* Previous surgery to controlateral axillary region.\n* Previous radiotherapy to ipsilateral or controlateral regional lymph nodes.\n* Non compliance with any inclusion criterion.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}